🇪🇺 DAMOCTOCOG ALFA PEGOL in European Union

EMA authorised DAMOCTOCOG ALFA PEGOL on 22 November 2018

Marketing authorisation

EMA — authorised 22 November 2018

  • Application: EMEA/H/C/004054
  • Marketing authorisation holder: Bayer AG
  • Local brand name: Jivi
  • Indication: Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
  • Status: approved

Read official source →

DAMOCTOCOG ALFA PEGOL in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is DAMOCTOCOG ALFA PEGOL approved in European Union?

Yes. EMA authorised it on 22 November 2018.

Who is the marketing authorisation holder for DAMOCTOCOG ALFA PEGOL in European Union?

Bayer AG holds the EU marketing authorisation.